Haloperydol (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Haloperydol" in Polish language version.

refsWebsite
Global rank Polish rank
4th place
7th place
2nd place
6th place
4,294th place
205th place
924th place
75th place
low place
462nd place
8,738th place
165th place

doi.org

dx.doi.org

  • Bernard Granger, Simona Albu, The haloperidol story, „Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists”, 17 (3), 2005, s. 137–140, DOI10.1080/10401230591002048, PMID16433054 [dostęp 2022-10-18] (ang.).
  • P.A. Janssen i inni, Chemistry and pharmacology of CNS depressants related to 4-(4-hydroxy-phenylpiperidino)butyrophenone. I. Synthesis and screening data in mice, „Journal of Medicinal and Pharmaceutical Chemistry”, 1, 1959, s. 281–297, DOI10.1021/jm50004a007, PMID14406750 [dostęp 2022-10-18] (ang.).
  • K. Igarashi i inni, Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP, „Life Sciences”, 57 (26), 1995, s. 2439–2446, DOI10.1016/0024-3205(95)02240-5, PMID8847965 [dostęp 2022-10-18] (ang.).
  • E. Usuki i inni, Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes, „Chemical Research in Toxicology”, 9 (4), 1996, s. 800–806, DOI10.1021/tx960001y, PMID8831826 [dostęp 2022-10-18] (ang.).
  • D.W. Eyles i inni, Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem, „Life Sciences”, 60 (8), 1997, s. 529–534, DOI10.1016/s0024-3205(96)00656-x, PMID9042387 [dostęp 2022-10-18] (ang.).
  • Ho-Jin Kang i inni, Neurotoxic pyridinium metabolites of haloperidol are substrates of human organic cation transporters, „Drug Metabolism and Disposition: The Biological Fate of Chemicals”, 34 (7), 2006, s. 1145–1151, DOI10.1124/dmd.105.009126, PMID16624869 [dostęp 2022-10-18] (ang.).
  • Kathryn M. Avent, J.J. DeVoss, Elizabeth M.J. Gillam, Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites, „Chemical Research in Toxicology”, 19 (7), 2006, s. 914–920, DOI10.1021/tx0600090, PMID16841959 [dostęp 2022-10-18] (ang.).

drugbank.ca

mp.pl

indeks.mp.pl

  • Haloperydol, [w:] Indeks Leków MP, lista preparatów, Medycyna Praktyczna [dostęp 2022-10-18].

nih.gov

ncbi.nlm.nih.gov

  • Bernard Granger, Simona Albu, The haloperidol story, „Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists”, 17 (3), 2005, s. 137–140, DOI10.1080/10401230591002048, PMID16433054 [dostęp 2022-10-18] (ang.).
  • P.A. Janssen i inni, Chemistry and pharmacology of CNS depressants related to 4-(4-hydroxy-phenylpiperidino)butyrophenone. I. Synthesis and screening data in mice, „Journal of Medicinal and Pharmaceutical Chemistry”, 1, 1959, s. 281–297, DOI10.1021/jm50004a007, PMID14406750 [dostęp 2022-10-18] (ang.).
  • K. Igarashi i inni, Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP, „Life Sciences”, 57 (26), 1995, s. 2439–2446, DOI10.1016/0024-3205(95)02240-5, PMID8847965 [dostęp 2022-10-18] (ang.).
  • E. Usuki i inni, Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes, „Chemical Research in Toxicology”, 9 (4), 1996, s. 800–806, DOI10.1021/tx960001y, PMID8831826 [dostęp 2022-10-18] (ang.).
  • D.W. Eyles i inni, Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem, „Life Sciences”, 60 (8), 1997, s. 529–534, DOI10.1016/s0024-3205(96)00656-x, PMID9042387 [dostęp 2022-10-18] (ang.).
  • Ho-Jin Kang i inni, Neurotoxic pyridinium metabolites of haloperidol are substrates of human organic cation transporters, „Drug Metabolism and Disposition: The Biological Fate of Chemicals”, 34 (7), 2006, s. 1145–1151, DOI10.1124/dmd.105.009126, PMID16624869 [dostęp 2022-10-18] (ang.).
  • Kathryn M. Avent, J.J. DeVoss, Elizabeth M.J. Gillam, Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites, „Chemical Research in Toxicology”, 19 (7), 2006, s. 914–920, DOI10.1021/tx0600090, PMID16841959 [dostęp 2022-10-18] (ang.).

pubchem.ncbi.nlm.nih.gov

sigmaaldrich.com

uakron.edu

ull.chemistry.uakron.edu